Yan C, Zhao L, Zhang X, Chu Z, Zhou T, Zhang Y, Geng S, Guo K. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro.
J Biophotonics 2024;
17:e202300356. [PMID:
38041219 DOI:
10.1002/jbio.202300356]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 11/15/2023] [Accepted: 11/15/2023] [Indexed: 12/03/2023]
Abstract
Cold atmospheric plasma (CAP) has been reported to kill melanoma cells in vitro and in vivo. BRAF and MEK inhibitors are targeted therapy agents for advanced melanoma patients with BRAF mutations. However, low overall survival and relapse-free survival are still tough challenges due to drug resistance. In this study, we confirmed that CAP alleviated innate drug resistance and promoted the anti-tumor effect of targeted therapy in A875 and WM115 melanoma cells in vitro. Further, we revealed that CAP altered the expression of various molecules concerning MAPK and PI3K-AKT pathways in A875 cells. This study demonstrates that CAP promises to work as adjuvant treatment with targeted therapy to overcome drug resistance for malignant tumors in future.
Collapse